Study Of 91,000 Patients Finds Ozempic-Class Drugs Slash Heart Attack Risk By 14%

Beyond Weight Loss: GLP-1 Drugs Tied to 14% Drop in Heart Attacks, Strokes, and Cardiovascular Death

Medications many people now take for diabetes and weight loss may be doing far more than shrinking waistlines and lowering blood sugar. A sweeping new analysis of more than 91,000 patients reveals that drugs like semaglutide and liraglutide significantly reduce the risk of heart attacks, strokes, and death from heart disease in the people most vulnerable to these events.

Heart disease remains the planet’s number-one killer, claiming roughly 17.9 million lives every year and accounting for about 32% of all deaths worldwide. For people already living with type 2 diabetes, obesity, or prior heart problems, the danger is even greater. Standard treatments have improved survival, but high-risk patients still suffer devastating cardiovascular events at alarming rates. This new research, a systematic review and meta-analysis published in Cardiovascular Diabetology – Endocrinology Reports in 2026, suggests that a class of drugs initially designed to manage blood sugar could help narrow that gap.

Researchers Pooled Data From 91,000 Patients Across 11 GLP-1 Trials

A team of researchers from the School of Medicine at Anglia Ruskin University in the United Kingdom set out to answer a straightforward but high-stakes question: do GLP-1 receptor agonists, a family of medications that mimic a natural gut hormone, actually protect the heart over the long term in people who need that protection most?

Rather than conduct a new experiment, the team pooled data from existing large-scale clinical trials. They searched three major medical databases for studies published between January 2015 and May 2025, requiring that each study randomly assign participants to receive either the drug or a placebo, with neither patients nor doctors knowing which was which. Each trial also had to include at least 3,000 participants and follow them for at least 12 months. After sorting through 645 studies and screening for eligibility, the team narrowed the list to 11 large trials enrolling 91,490 participants with a pooled average age of about 64 years. Roughly 66% were male. Average follow-up was 2.7 years. The drugs studied included seven GLP-1 receptor agonists: liraglutide, lixisenatide, semaglutide, exenatide, albiglutide, dulaglutide, and efpeglenatide.

Heart Attack and Stroke Risk Dropped 14% With GLP-1 Drugs in High-Risk Patients

Across all 11 trials, patients on GLP-1 receptor agonists experienced a 14% reduction in their combined risk of heart-related death, non-fatal heart attack, and non-fatal stroke compared with placebo.

Benefits showed up across every single category measured. Heart-related death was reduced by 13%, death from any cause by 13%, non-fatal heart attacks by 15%, non-fatal strokes by 15%, and hospitalizations for heart failure by 12%.

One pressing question remained: were these heart benefits simply a byproduct of better blood sugar control? To test this, the researchers excluded the one trial, known as SELECT, that enrolled patients who were overweight or obese with existing heart disease but no diabetes. Even then, the reduction in cardiovascular events held firm. A focused look at the four trials testing semaglutide alone showed an even larger benefit: an 18% risk reduction with virtually no inconsistency between studies. The researchers cautioned that head-to-head trials comparing individual drugs have not been conducted, making it premature to declare any single medication superior.

Researchers also examined whether the drugs caused serious harm. Across 10 of the 11 trials, the difference in severe low blood sugar episodes between drug and placebo groups was negligible. Pancreas inflammation, a long-standing theoretical concern with this class of medication, occurred at rates below 1% with no meaningful increase compared with placebo, directly addressing two of the biggest fears patients and doctors have had about these drugs for years.

One consistent downside was stomach-related side effects, which showed up across nearly every trial. Nausea, vomiting, and diarrhea were reported far more frequently in patients taking the medications, with the gap between groups ranging from less than 1% to as high as 17% in some trials. These side effects remain a real barrier to sticking with treatment long enough to see cardiovascular benefit.

GLP-1 Drugs Should Be Part of Heart Disease Prevention, Authors Say

Researchers rated the overall quality of evidence as high, giving them strong confidence that the results reflect the true effect of these drugs. The authors argue that clinicians should consider GLP-1 receptor agonists not just as tools for blood sugar management or weight loss, but as part of a broader strategy to reduce cardiovascular risk in high-risk patients.

For the tens of millions of people worldwide living at the intersection of diabetes, obesity, and heart disease, these results carry real weight. The question now is not simply whether these drugs can help the heart in high-risk patients. This analysis adds strong evidence that they can. The harder question is whether the people most likely to benefit can access them.

---

Disclaimer: This article is based on a published peer-reviewed study and is intended for informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before making any changes to medications or treatment plans.

---